<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">To document the safety and tolerance of American ginseng root extract, a randomized, phase II clinical trial in 3- to 12-year-old children was conducted. No serious adverse events for the oral consumption of ginsenosides were reported in either animal or 
 <italic>in vitro</italic> studies when using the Canadian Acute Respiratory Infection Flu Scale [
 <xref rid="bib102" ref-type="bibr">102</xref>]. A double-blinded clinical trial with 168 participants was conducted in Melbourne (Australia), wherein they administered 
 <italic>P. ginseng</italic> capsules (100 mg) twice a day for 24 weeks [Clinical Trials Register (ANZCTR): 
 <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/ACTRN12610000768099.aspx" id="intref0090" xmlns:xlink="http://www.w3.org/1999/xlink">ACTRN12610000768099</ext-link>]; it suggested that this treatment was safe and of therapeutic value, resulting in symptomatic relief in patients with COPD [
 <xref rid="bib103" ref-type="bibr">103</xref>]. In a double-blind, pilot trial involving nine participants with COPD and 14 control participants (57–73 years old), researchers compared 
 <italic>P. ginseng</italic> (200 mg twice daily for four weeks) with a placebo in Guangdong Province, China, ANZCTR (ACTRN: 12613000382774), and they found that the ginseng was well tolerated with no adverse events [
 <xref rid="bib104" ref-type="bibr">104</xref>].
</p>
